PTC Therapeutics (PTCT) chief business officer reports tax sell-to-cover stock sales

Rhea-AI Filing Summary

PTC Therapeutics, Inc. (PTCT) chief business officer Eric Pauwels reported automatic sales of common stock to cover tax withholding from restricted stock unit (RSU) vesting. On January 6, 2026, he sold 1,789 shares of common stock at $76.95 per share. On January 7, 2026, he sold an additional 1,352 shares at $77.48 per share. Both transactions were executed under an irrevocable sell-to-cover election entered into when the RSU grants were accepted and were made to satisfy tax withholding obligations tied to the vesting of RSUs granted in January 2023 and January 2025. After these transactions, Pauwels directly beneficially owned 87,489 shares of PTC Therapeutics common stock.

Insider Trade Summary

Net Seller: 3,141 shares ($242,417)

Net Sell 2 txns

Insider Pauwels Eric

Role CHIEF BUSINESS OFFICER

Sold 3,141 shs ($242K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,352	$77.48	$105K
Sale	Common Stock	1,789	$76.95	$138K

Holdings After Transaction: Common Stock — 87,489 shares (Direct)

Footnotes (1)

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,500 RSUs from a January 3, 2025 grant of 22,000 RSUs. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 5, 2023 grant of 18,000 RSUs.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pauwels Eric

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF BUSINESS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S		1,789(1)	D	$76.95	88,841	D
Common Stock	01/07/2026		S		1,352(2)	D	$77.48	87,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,500 RSUs from a January 3, 2025 grant of 22,000 RSUs.

2. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 5, 2023 grant of 18,000 RSUs.

	/s/ Avraham S. Adler, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did PTC Therapeutics (PTCT) report in this Form 4?

The filing reports that Eric Pauwels, chief business officer of PTC Therapeutics, Inc., sold small blocks of common stock in two transactions on January 6 and 7, 2026, in connection with RSU vesting.

How many PTC Therapeutics (PTCT) shares did Eric Pauwels sell and at what prices?

On January 6, 2026, Pauwels sold 1,789 shares at $76.95 per share. On January 7, 2026, he sold 1,352 shares at $77.48 per share.

Why were the PTC Therapeutics (PTCT) shares sold by Eric Pauwels?

The footnotes state the sales represent shares automatically sold under an irrevocable sell-to-cover election entered into upon acceptance of the RSU grants, in order to satisfy tax withholding obligations when RSUs vested.

Which RSU grants were related to these PTC Therapeutics (PTCT) insider sales?

The January 6, 2026 sale relates to the vesting of 5,500 RSUs from a January 3, 2025 grant of 22,000 RSUs. The January 7, 2026 sale relates to the vesting of 4,500 RSUs from a January 5, 2023 grant of 18,000 RSUs.

How many PTC Therapeutics (PTCT) shares does Eric Pauwels own after these transactions?

Following the reported transactions, Pauwels beneficially owned 87,489 shares of PTC Therapeutics common stock held directly.

Is this PTC Therapeutics (PTCT) Form 4 filed by a director or an officer?

The reporting person, Eric Pauwels, is identified as an officer of PTC Therapeutics with the title chief business officer, and the form is filed by one reporting person.